Skip to main content

Table 1 Expression scores for eIF4E (4E), 4E-BP1 (BP1), 4E-BP2 (BP2), phospho-4E-BP1 (pBP1) and Ki67, and estimates of eIF4E activity in matched pre- and post-treatment samples from patients treated with 11-14 days of everolimus.

From: Response to mTOR inhibition: activity of eIF4E predicts sensitivity in cell lines and acquired changes in eIF4E regulation in breast cancer

 

pre-treatment

post-treatment

Patient

4E

BP1

BP2

pBP1

activity

Ki67

4E

BP1

BP2

pBP1

activity

Ki67

1

6

5

5

6

6.5

15.5

0

0

6

0

-1.5

23.1

2

3

5

5

5

3

6.0

0

3

5

0

-2

0.9

3

3

3

5

4

3

7.6

5

4

5

3

4.25

2.7

4

5

6

6

6

5

22.1

6

7

7

6

5.5

16.7

5

4

6

4

6

4.5

44.6

4

4

4

3

3.5

29.7

6

4

0

6

6

5.5

34.2

5

5

5

4

4.5

23.0

7

3

6

5

5

1.75

4.2

4

4

4

0

2

2.7

8

4

3

4

2

3.25

1.6

3

0

4

3

3.5

4.4

9

5

7

7

6

4.5

15.3

5

6

7

5

4.25

6.8

10

5

7

6

5

4.25

22.6

5

3

6

2

3.75

6.5

11

5

0

6

2

4.5

18.4

5

0

4

0

4

7.4

12

5

3

6

6

5.75

3.6

6

6

7

3

4.25

47.2

13

4

4

0

5

5.5

10.1

6

5

5

2

4.5

3.6

14

6

4

0

6

8

17.4

4

4

6

2

2.5

10.1

15

5

0

0

6

8

10.2

4

0

7

5

4.75

17.8

16

5

4

0

4

6

10.6

6

4

6

2

4.5

13.0

17

4

4

2

6

5.5

16.2

6

3

5

4

6

8.4

18

0

0

0

4

2

6.2

4

2

7

0

1.75

5.2

19

4

4

0

5

5.5

18.2

7

7

5

3

5.5

9.0

20

6

4

0

7

8.5

18.0

5

6

7

5

4.25

3.8

21

5

4

6

6

5.5

20.0

0

0

5

5

1.25

13.4

22

5

4

2

4

5.5

6.8

4

4

7

3

2.75

5.3